These 3 Stocks Are Crushing The "magnificent Seven&q…

1. Moderna

Moderna (MRNA +14.21%) is delivering an even better year than in 2020 and 2021, when the company vaulted into the limelight with its COVID-19 vaccine. The biotech stock has skyrocketed more than 620% so far in 2026.

Expand

NASDAQ: MRNA

Moderna

Premium Feature

Moneyball Superscore

58/100

Today’s Change

(14.21%) $28.00

Current Price

$225.00

Key Data Points

Market Cap

$90BMarket cap calculated using publicly traded s outstanding only. Does not include unlisted, private, or dual-class non-traded s. Implied market cap may vary.

Day’s Range

$197.17 – $225.00

52wk Range

$22.28 – $225.00

Volume

114.8K

Avg Vol

18.1M

Gross Margin

12.57%

COVID isn’t the catalyst for Moderna this time, though. Instead, it’s the company’s personalized messenger RNA (mRNA) cancer vaccine, intismeran autogene. In August 2026, Moderna and its big partner, Merck (MRK +2.26%), announced impressive results from a late-stage study of the cancer vaccine combined with Merck’s blockbuster immunotherapy Keytruda in the treatment of melanoma.

Moderna has high hopes that intismeran autogene will prove safe and effective for treating multiple types of cancer in addition to melanoma. The company, along with Merck, is evaluating the experimental vaccine in combination with Keytruda in clinical studies targeting lung, kidney, and bladder cancer, among others.

2. Twist Bioscience

Twist Bioscience (TWST +5.08%) makes synthetic DNA. Scientists and drug developers use this DNA. Twist’s silicon-based manufacturing platform allows the company to produce DNA more efficiently, faster, and more cheaply than older methods.

Synthetic DNA is selling hotcakes these days. Twist reported its 14th consecutive quarter of revenue growth in August 2026, with revenue jumping 23% year over year to $118.4 million. The company is on track to reach adjusted EBITDA breakeven in the fourth quarter of 2026.

Expand

NASDAQ: TWST

Twist Bioscience

Premium Feature

Moneyball Superscore

83/100

Today’s Change

(5.08%) $7.73

Current Price

$159.78

Key Data Points

Market Cap

$11BMarket cap calculated using publicly traded s outstanding only. Does not include unlisted, private, or dual-class non-traded s. Implied market cap may vary.

Day’s Range

$152.14 – $168.93

52wk Range

$23.30 – $219.71

Volume

26.7K

Avg Vol

2.1M

Gross Margin

51.97%

Investors have rewarded Twist for its commercial success. The stock has more than quintupled year to date, even after a significant pullback in recent weeks. That return is more than 16 times greater than the return of the best-performing Magnificent Seven stock this year.

3. 10X Genomics

10X Genomics (TXG +4.36%) hasn’t delivered the impressive revenue growth that Twist has. The life sciences technology company’s sales increased only 3% year over year in its latest quarter.

However, 10X Genomics’ stock has jumped nearly as much as Twist’s so far this year, up almost 400%. Similar to Twist, 10X’s performance has been dampened by a recent pullback.

Expand

NASDAQ: TXG

10x Genomics

Premium Feature

Moneyball Superscore

73/100

Today’s Change

(4.36%) $3.37

Current Price

$80.65

Key Data Points

Market Cap

$11BMarket cap calculated using publicly traded s outstanding only. Does not include unlisted, private, or dual-class non-traded s. Implied market cap may vary.

Day’s Range

$78.52 – $85.12

52wk Range

$11.16 – $102.81

Volume

4.1K

Avg Vol

3.3M

Gross Margin

70.58%

Several factors explain 10X Genomics’ momentum. The company won a patent infringement lawsuit against Parse Biosciences, a subsidiary of Qiagen (NYSE: QGEN). It launched a new product, Atera, which profiles gene activity at the single-cell level across larger tissue areas with greater sensitivity than previous technologies. 10X also introduced Sentira, a product that reduces spatial data processing times from hours to minutes.

Are they buys?

High-flying growth stocks are often popular with Wall Street analysts. However, that isn’t always the case.

The consensus 12-month price target for Moderna is roughly 49% below its current price. Unsurprisingly, only three of the 20 analysts who have rated the biotech stock over the last three months recommended buying it.

Many on Wall Street also expect Twist Bioscience’s momentum to falter. The average price target for the stock is 11% below the current price. On the other hand, eight of 11 analysts recommend buying Twist’s s.

Similarly, the consensus price target for 10X Genomics is around 16% below its current price. Of the 16 analysts who rated the stock in the last three months, seven gave it a “buy” rating and nine recommended holding.

I don’t always agree with Wall Street, but I suspect analysts are right that the stocks of Moderna, Twist Bioscience, and 10X Genomics could slide over the next 12 months. For investors seeking near-term profits, other stocks offer more attractive risk-reward propositions. However, any significant sell-offs could present great buying opportunities for long-term investors.

Read Next

Oct 10, 2026 •By Adria Cimino

Moderna Now Trades 61% Above Wall Street’s Average Price Target. Should You Sell?

Oct 9, 2026 •By Joe Tenebruso

Why Moderna Stock Surged Today

Oct 9, 2026 •By Prosper Junior Bakiny

This Stock Is Up More than 560% This Year, but It Could Drop by 38%, According to Wall Street

Oct 7, 2026 •By Brendan Coffey

Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?

Oct 6, 2026 •By David Jagielski, CPA

Is Now the Time to Cash Out of the S&P 500’s Top 3 Stocks of 2026?

Sep 30, 2026 •By Adria Cimino

Prediction: Moderna Stock Will Soar 100% by 2030

About the Author

Keith Speights is a contributing Motley Fool healthcare analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, technology, and marijuana. Prior to The Motley Fool, Keith was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.

TMFFishBiz

Stocks Mentioned

Motley Fool Stock Advisor’s Latest Pick

Get Access

—% Avg Return

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.